Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Tislelizumab with or without TACE in Advanced HCC
NCT05842317Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 6 months. Started Sep 2022; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05842317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842317.